+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastric Cancer Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5939683
The gastric cancer drugs market size has grown rapidly in recent years. It will grow from $3.91 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth observed in the historical period can be ascribed to the rise in pharmaceutical research and development (R&D) expenditure, augmented healthcare spending, robust economic growth in emerging markets, and the swift expansion of the elderly population.

The gastric cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be ascribed to the increase in the incidence rate of gastric cancer, a robust pipeline of drugs, a surge in acquisitions and partnerships for drug development, a rise in healthcare expenditure, high potential in emerging economies, a growing geriatric population, and revised FDA regulations aimed at facilitating biologics drug development. Major trends expected in the forecast period include strategic collaborations and agreements to expand product portfolios, partnerships with other companies or government bodies to expedite the development of new drugs, an increase in the number of pipeline studies for the development of gastric cancer drugs, investments in AI solutions to reduce R&D costs, the development of next-generation biologics to enhance revenue and market share, and the use of CRISPR-Cas9 technology in new drug developments or for improved results in gastric cancer treatments.

The rising prevalence of obesity and an increasing number of smokers have contributed to a higher incidence of gastric cancer. Tobacco consumption and an unhealthy diet are identified as risk factors for stomach cancer. According to the American Institute for Cancer Research's 2020 estimates, approximately 27,600 cases of stomach cancer were projected to be diagnosed, with 16,980 in men and 10,620 in women. The growing number of gastric cancer cases is expected to fuel the expansion of the gastric cancer drugs market.

The expanding global aging population is anticipated to drive the future growth of the gastric cancer drug market. An aging population is characterized by a significant proportion of individuals aged 65 and above, resulting from increased life expectancy and reduced birth rates. This demographic shift necessitates tailored treatment options, including drugs, to accommodate the specific needs and tolerances of elderly patients who may have limited tolerance for certain cancer treatments such as surgery or chemotherapy. For example, as reported by The Print in August 2021, India's elderly population (aged 60 and above) is expected to reach 194 million by 2031, reflecting a 41% increase from 138 million in 2021, according to the National Statistical Office's Elderly in India 2021. Consequently, the gastric cancer drug market is poised for growth due to the expanding elderly population.

Numerous companies are employing combination therapies as a strategy to combat gastric cancer effectively. Combination therapies involve the simultaneous use of two or more drugs to treat a single disease, enhancing patient care. For instance, in January 2021, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, announced the FDA approval of Enhertu (trastuzumab deruxtecan) in the US for treating adult patients with locally progressed or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. This therapy, combining trastuzumab with a fluoropyrimidine- and platinum-based chemotherapy, is administered to individuals facing advanced gastric cancer or GEJ adenocarcinoma who have previously undergone a trastuzumab-based regimen.

Major companies in the gastric cancer drugs market are introducing innovative medications such as Nivolumab (Opdivo) to maintain a competitive edge. Nivolumab is an immune checkpoint inhibitor belonging to the Programd death receptor-1 (PD-1) blockers class, used in cancer therapy. The incorporation of immune checkpoint inhibitors in gastric cancer treatment aligns with the broader effort to develop more targeted and effective therapies for the disease. For example, in April 2021, Bristol-Myers Squibb Company, a US-based biopharmaceutical company, received FDA approval for Opdivo (nivolumab) injection for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, irrespective of PD-L1 expression status.

In March 2021, Amgen Inc., a US-based biopharmaceutical company, completed the acquisition of Five Prime Therapeutics, Inc. for $1.9 billion. This strategic move by Amgen enhances its oncology product portfolio, assets for gastric cancer treatment, monoclonal antibody manufacturing capabilities, and drug development capabilities, particularly for biological drugs targeting advanced gastric or gastroesophageal junction (GEJ) cancer. Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing immuno-oncology protein therapeutics for cancer treatment.

Major companies operating in the gastric cancer drugs market report are F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca PLC, GlaxoSmithKline PLC, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, GSK, Gilead Sciences, BMS, Ascedis Health.

North America was the largest region in the gastric cancer drugs market in 2023. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary types of gastric cancer drugs include doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. Sunitinib functions as both a chemotherapeutic agent and a receptor tyrosine kinase inhibitor, employed in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). These drugs are administered via oral and parenteral routes and find application in hospitals, clinics, and other healthcare settings.

The gastric cancer drugs market research report is one of a series of new reports that provides gastric cancer drugs market statistics, including gastric cancer drugs industry global market size, regional shares, competitors with a gastric cancer drugs market share, detailed gastric cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer drugs industry. This gastric cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer drugs market consists of sales of cyramza, docetaxel, and doxorubicin hydrochloride. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary2. Gastric Cancer Drugs Market Characteristics3. Gastric Cancer Drugs Market Trends and Strategies
4. Gastric Cancer Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Gastric Cancer Drugs Market Size and Growth
5.1. Global Gastric Cancer Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Gastric Cancer Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Gastric Cancer Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Gastric Cancer Drugs Market Segmentation
6.1. Global Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Doxorubicin Hydrochloride
  • Sunitinib
  • Docetaxel
  • Mitomycin
  • Fluorouracil
  • Imatinib
  • Trastuzumab
6.2. Global Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
6.3. Global Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other End-users
7. Gastric Cancer Drugs Market Regional and Country Analysis
7.1. Global Gastric Cancer Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Gastric Cancer Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Gastric Cancer Drugs Market
8.1. Asia-Pacific Gastric Cancer Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Gastric Cancer Drugs Market
9.1. China Gastric Cancer Drugs Market Overview
9.2. China Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Gastric Cancer Drugs Market
10.1. India Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Gastric Cancer Drugs Market
11.1. Japan Gastric Cancer Drugs Market Overview
11.2. Japan Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Gastric Cancer Drugs Market
12.1. Australia Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Gastric Cancer Drugs Market
13.1. Indonesia Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Gastric Cancer Drugs Market
14.1. South Korea Gastric Cancer Drugs Market Overview
14.2. South Korea Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Gastric Cancer Drugs Market
15.1. Western Europe Gastric Cancer Drugs Market Overview
15.2. Western Europe Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Gastric Cancer Drugs Market
16.1. UK Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Gastric Cancer Drugs Market
17.1. Germany Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Gastric Cancer Drugs Market
18.1. France Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Gastric Cancer Drugs Market
19.1. Italy Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Gastric Cancer Drugs Market
20.1. Spain Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Gastric Cancer Drugs Market
21.1. Eastern Europe Gastric Cancer Drugs Market Overview
21.2. Eastern Europe Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Gastric Cancer Drugs Market
22.1. Russia Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Gastric Cancer Drugs Market
23.1. North America Gastric Cancer Drugs Market Overview
23.2. North America Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Gastric Cancer Drugs Market
24.1. USA Gastric Cancer Drugs Market Overview
24.2. USA Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Gastric Cancer Drugs Market
25.1. Canada Gastric Cancer Drugs Market Overview
25.2. Canada Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Gastric Cancer Drugs Market
26.1. South America Gastric Cancer Drugs Market Overview
26.2. South America Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Gastric Cancer Drugs Market
27.1. Brazil Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Gastric Cancer Drugs Market
28.1. Middle East Gastric Cancer Drugs Market Overview
28.2. Middle East Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Gastric Cancer Drugs Market
29.1. Africa Gastric Cancer Drugs Market Overview
29.2. Africa Gastric Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Gastric Cancer Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Gastric Cancer Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Gastric Cancer Drugs Market Competitive Landscape and Company Profiles
30.1. Gastric Cancer Drugs Market Competitive Landscape
30.2. Gastric Cancer Drugs Market Company Profiles
30.2.1. F. Hoffmann-La Roche
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Eli Lilly and Company
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Otsuka Pharmaceutical
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Jiangsu HengRui Medicine
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Biocon
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Gastric Cancer Drugs Market Other Major and Innovative Companies
31.1. Sanofi
31.2. PV Pharma Healthcare (India)
31.3. Roche India
31.4. Novartis Oncology
31.5. Arlak Biotech (India)
31.6. Healthkind labs Pvt. Ltd.
31.7. SwisscheM Healthcare Pvt.Ltd
31.8. Apikos Pharma
31.9. Kolaz biotech.
31.10. CStone Pharma (China)
31.11. CARsgen Therapeutics (China)
31.12. JW Therapeutics (China)
31.13. BeiGene(China)
31.14. Takeda Pharmaceuticals (Japan)
31.15. Astellas Pharma Inc (Japan)
32. Global Gastric Cancer Drugs Market Competitive Benchmarking33. Global Gastric Cancer Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Gastric Cancer Drugs Market
35. Gastric Cancer Drugs Market Future Outlook and Potential Analysis
35.1 Gastric Cancer Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Gastric Cancer Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Gastric Cancer Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Gastric Cancer Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for gastric cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Type: Imatinib; Trastuzumab; Other Types
2) By Route of Administration: Oral; Parenteral
3) By End-user: Hospitals; Clinics; Cancer Specialty Centers

Key Companies Mentioned: F. Hoffmann-La Roche; Eli Lilly and Company; Otsuka Pharmaceutical; Jiangsu HengRui Medicine; Biocon

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche
  • Eli Lilly and Company
  • Otsuka Pharmaceutical
  • Jiangsu HengRui Medicine
  • Biocon
  • Sanofi
  • PV Pharma Healthcare (India)
  • Roche India
  • Novartis Oncology
  • Arlak Biotech (India)
  • Healthkind labs Pvt. Ltd.
  • SwisscheM Healthcare Pvt.Ltd
  • Apikos Pharma
  • Kolaz biotech.
  • CStone Pharma (China)
  • CARsgen Therapeutics (China)
  • JW Therapeutics (China)
  • BeiGene(China)
  • Takeda Pharmaceuticals (Japan)
  • Astellas Pharma Inc (Japan)
  • Daiichi Pharmaceutical and Sankyo (Japan)
  • AQVIDA GmbH
  • Baxter International Inc. (UK)
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Veropharm
  • Biocad
  • Bristol-Myers Squibb
  • Celon Pharma
  • Celltrion Inc.
  • Imugene Limited
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sandoz AG (A Novartis Division)
  • Eurofarma Laboratórios S.A.
  • TUTEUR ArgentinaPierre Fabre Group
  • Celnova Pharma
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO)
  • Gulf Pharmaceutical Industries (Julphar)
  • Abbott Laboratories
  • Mylan Laboratories
  • GSK
  • Gilead Sciences
  • BMS
  • Ascedis Health

Methodology

Loading
LOADING...